Albuterol

Albuterol

SCHEMBL7775807

CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CCCCCCCCCC(=O)O

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB2

The experimentally established mechanism targets of Albuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 11/20 0.70
ADRB1 P08588 3/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2D6 P10635 1/20 0.70
TSHR P16473 1/20 0.70
NFKB1 P19838 1/20 0.70
HIF1A Q16665 1/20 0.70
TDP1 Q9NUW8 1/20 0.69
PMP22 Q01453 1/20 0.67
ADRB3 P13945 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Stearic Acid SCHEMBL5145217 1.00 ADRB2 (0.70) ADRB2ADRB1CYP1A2CYP2D6TSHR
Albuterol SCHEMBL7778379 1.00 ADRB2 (0.70) ADRB2ADRB1CYP1A2CYP2D6TSHR
Stearic Acid SCHEMBL518159 0.95 PMP22 (0.73) ADRB2ADRB1CYP1A2CYP2D6TSHR
Oleic Acid SCHEMBL6258016 0.94 ADRB2 (0.62) ADRB2ADRB1CYP1A2CYP2D6TSHR
Stearic Acid SCHEMBL518158 0.86 PMP22 (0.72) ADRB2ADRB1CYP1A2CYP2D6TSHR
Albuterol SCHEMBL6264324 0.86 ADRB2 (0.65) ADRB2ADRB1CYP1A2CYP2D6TSHR
Albuterol SCHEMBL6838948 0.85 ADRB2 (0.87) ADRB2ADRB1CYP1A2CYP2D6TSHR
Albuterol SCHEMBL4913 0.84 ADRB2 (1.00) ADRB2ADRB1CYP1A2CYP2D6TSHR
Albuterol SCHEMBL121596 0.84 ADRB2 (1.00) ADRB2ADRB1CYP1A2CYP2D6TSHR
Levosalbutamol SCHEMBL4003 0.84 ADRB2 (1.00) ADRB2ADRB1CYP1A2CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6255502-B1 DRUG DELIVERY THROUGH SKIN, INTESTINAL, ORAL, NASAL, AND RECTAL MUCOSA ENHANCED BY FORMING INCLUSION COMPLEXES WITH CYCLODEXTRINS (SOLUBILIZERS/STABILIZERS) AND ACID-ADDITION SALTS OF DRUGS (CODEINE) AND A FATTY/BILE ACID FARMARC NEDERLAND B.V. (NL) 2001-07-03 US claimed
JP-2001508027-A 2001-06-19 JP claimed
EP-1024833-A1 Pharmaceutical composition containing acid addition salt of basic drug FARMARC NEDERLAND B.V. (NL) 2000-08-09 EP claimed
CN-1230123-A Inclusion complex containing indole selective serotonin agonist FARMARC NEDERLAND BV (NL) 1999-09-29 CN claimed
WO-1998002187-A1 PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF BASIC DRUG FARMARC NEDERLAND B.V. (NL) 1998-01-22 WO claimed
US-6255502-B1 DRUG DELIVERY THROUGH SKIN, INTESTINAL, ORAL, NASAL, AND RECTAL MUCOSA ENHANCED BY FORMING INCLUSION COMPLEXES WITH CYCLODEXTRINS (SOLUBILIZERS/STABILIZERS) AND ACID-ADDITION SALTS OF DRUGS (CODEINE) AND A FATTY/BILE ACID FARMARC NEDERLAND B.V. (NL) 2001-07-03 US disclosed
EP-1024833-A1 Pharmaceutical composition containing acid addition salt of basic drug FARMARC NEDERLAND B.V. (NL) 2000-08-09 EP disclosed
CN-1230123-A Inclusion complex containing indole selective serotonin agonist FARMARC NEDERLAND BV (NL) 1999-09-29 CN disclosed
WO-1998002187-A1 PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF BASIC DRUG FARMARC NEDERLAND B.V. (NL) 1998-01-22 WO disclosed